The hardware and bandwidth for this mirror is donated by dogado GmbH, the Webhosting and Full Service-Cloud Provider. Check out our Wordpress Tutorial.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]dogado.de.

BayesOrdDesign: Bayesian Group Sequential Design for Ordinal Data

The proposed group-sequential trial design is based on Bayesian methods for ordinal endpoints, including three methods, the proportional-odds-model (PO)-based, non-proportional-odds-model (NPO)-based, and PO/NPO switch-model-based designs, which makes our proposed methods generic to be able to deal with various scenarios. Richard J. Barker, William A. Link (2013) <doi:10.1080/00031305.2013.791644>. Thomas A. Murray, Ying Yuan, Peter F. Thall, Joan H. Elizondo, Wayne L.Hofstetter (2018) <doi:10.1111/biom.12842>. Chengxue Zhong, Haitao Pan, Hongyu Miao (2021) <doi:10.48550/arXiv.2108.06568>.

Version: 0.1.2
Depends: R (≥ 3.3.0)
Imports: ordinal, schoolmath, coda, gsDesign, superdiag, ggplot2, madness, rjmcmc, R2jags, rjags, methods
Suggests: testthat (≥ 3.0.0)
Published: 2022-11-14
DOI: 10.32614/CRAN.package.BayesOrdDesign
Author: Chengxue Zhong [aut, cre], Haitao Pan [aut], Hongyu Miao [aut]
Maintainer: Chengxue Zhong <czhong9106 at gmail.com>
License: GPL-2
NeedsCompilation: no
CRAN checks: BayesOrdDesign results

Documentation:

Reference manual: BayesOrdDesign.pdf

Downloads:

Package source: BayesOrdDesign_0.1.2.tar.gz
Windows binaries: r-devel: BayesOrdDesign_0.1.2.zip, r-release: BayesOrdDesign_0.1.2.zip, r-oldrel: BayesOrdDesign_0.1.2.zip
macOS binaries: r-release (arm64): BayesOrdDesign_0.1.2.tgz, r-oldrel (arm64): BayesOrdDesign_0.1.2.tgz, r-release (x86_64): BayesOrdDesign_0.1.2.tgz, r-oldrel (x86_64): BayesOrdDesign_0.1.2.tgz
Old sources: BayesOrdDesign archive

Linking:

Please use the canonical form https://CRAN.R-project.org/package=BayesOrdDesign to link to this page.

These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.
Health stats visible at Monitor.